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Conclusion: The early nutritional assessment and the multidisciplinary approach
showed a reduction in the percentage of the weight loss, due to an increase of calories
and proteins intake (oral food) together with an increase in oral nutritional supple-
ments. Serum proteins and albumin changed from 6,2mg/dl (þ/- 0,6) and 3,2mg/dl
(þ/- 0,6) at T0 to 6,3mg/dl (þ/- 0,5) and 3,4mg/dl (0,6) at T2.
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Background:High NLR is an established adverse prognostic feature in pancreatic can-
cer, however his change over the time during the entire course of the disease and its
ability to precisely predict survival have never been investigated.
Methods:We analysed 2975 blood cell counts from 85metastatic pancreatic cancer
patients to build a NLR-over-the-time-curve from the beginning of the disease history
until death. The shape of NLR-over-the-time-curve was evaluated and the minumum
timepoints needed to predict the entire curve was assessed using the error-vs-partial-
measurmnets function.
Results: The NLR-over-the-time-curve was found to have a clear rectilinear shape in all
analyzed patients. The best fitting linear curves proved to have a coefficient of determi-
nation, namely “R-squared”, about of 24-25% for nearly all patients. In order to inves-
tigate how linear extrapolations of initial (partial) data can predict the whole
phenomenon, we compared such extrapolations with the final best fitting curve in
terms of R-squared and considered the prediction to be adequate when the correspond-
ing R-squared attained the same final value of the best fitting curve. Overall, the R-
squared of 24-25% could be attained in as early as three months of blood cell count
measurements. Since the near-end-of-life NLR was> 4 in 95% of cases, then a precise
overall survival prediction was possible using NLR values assessed during the first three
months of patient management.
Conclusion: Building the NLR-over-the-time-curve is a precise tool to predict overall
survival in pancreatic cancer patients. Future studies need to understand how interven-
tions to change the slope of the curve (such as anti-inflammatory therapies) may
impact on prognosis.
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Background: Surgical resection remains the only curative treatment for non-metastatic
gastroesophageal (GE) cancer. A large cohort of GE cancers derived from a high-vol-
ume Italian center was analyzed to describe clinical outcomes and prognostic factors.
Methods: 338 patients (pts) diagnosed with GE cancers who underwent curative resec-
tion from 2007 to 2016 were considered. Variables analyzed were: age, sex, tumor loca-
tion, histology, tumor (T), nodal status (N), resection margin status (R), grade (G),
(neo) adjCT, adj CTRT, neutrophil/lymphocyte ratio (NLR) and lymphadenectomy
status (D1-D2-D3) . Statistical analysis was performed according to intention to treat
principle.
Results: Included pts were 131 women (39%) and 207men (61%), median age 75 years.
Adenocarcinomas (Lauren intestinal type) accounted for 69% (232 cases), 76 cases
were diffuse carcinomas (22%) and 30 of mixed histology (9%). In 182 cases TNM stage
was I or II (54%), 128 pts had stage III (38%) and 28 stage IV (8%). Median overall sur-
vival (mOS) was 33.8mo andmedian disease free survival (mDFS) 24mo. Adj CT was
administered in 98 cases (29%); 93 pts (28%) had adj CTRT and 26 (8%) neoadj CT.
D2 or D3 lymphadenectomy was performed in 182 pts, 54%.Median NLR was 2.52.
Statistically significant variables for mOS and/or DFS at univariate analysis were: age,
T, N, R, G, stage, tumor location, NLR and adjuvant chemotherapy. Pts with proximal
disease (GE junction-cardias, 41 patients, 12%) had the poorest survival (mOS 17.1 vs
36.4 months for others, p¼ 0.0025). A lowNLR was associated with higher mOS (44.
vs 27.8 months for NLR over median value, p¼ 0.0016). Results of multivariate analysis
are shown in Table 1.
Conclusions:Despite a short follow-up, our analysis performed on a large cohort of
consecutive pts showed the prognostic value of R for bothmDFS and OS.Moreover,
disease stage and adj CT administration were significantly correlated with mOS. A lon-
ger follow-up is needed to achieve more conclusive data.
Table: D22. Multivariate analysis for mDFS and OS
Variable mDFS (p value) mOS (p value)
Sex n.s. n.s.
Tumor location (GE-cardia vs others) n.s. n.s.
Histology (Lauren) n.s. n.s.
T (1-2 vs 3-4) n.s. n.s.
N (0 vs 1-2-3) n.s. n.s.
R (0 vs 1-2) 0.033* 0.001 *
G (3-4 vs 1-2) n.s. n.s.
Stage (I-II vs III vs IV) n.s. 0.012 *
NLR (> vs < median value) n.s. n.s.
Lymphadenectomy (D1 vs D2-D3) n.s. n.s.
Adj CTRT (no vs yes) n.s. n.s.
Neoadj CT (no vs yes) n.s. n.s.
Adj CT (no vs yes) n.s. 0.001 *
*: statistically significant; n.s.: not significant
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Background: Small bowel adenocarcinomas (SBA) are rare tumours with an increasing
incidence. The duodenum is the most common primary location. They are often spora-
dic, but Crohn’s disease and genetic syndromes have been indentified as risk factors.
Bowel occlusion and bleeding are common at clinical presentation. Surgical resection
represents the best option for resectable tumours. The role of adjuvant treatment has
not yet been established by randomised trials and in metastatic disease, the best treat-
ment is fluoropirimidine and platinum based chemotherapy.
Patients andmethods: In this retrospective observational study we enrolled patients
with histological diagnosis of SBA treated at two Italian Hospitals. Their clinical courses
and outcome were evaluated considering tumour location and treatment received.
According to Kimora Classification we divided duodenum-ampullary carcinoma in
intestinal and bilio-pancreatic type.
Results: 39 patients were evaluated. Median age at diagnosis was 66 years (range 29-
88); male/female 21/18. According to tumour location we identified 3 duodenum
adenocarcinomas (8%), 30(77%) duodenum-ampullary adenocarcinomas (23(59%)
intestinal and 7(17%) biliary type), 3(8%) jujunal and 3(8%) ileal adenocarcinomas. At
diagnosis the majority of the cases were stage II (16;41%) and G3 (15;23%) adenocarci-
nomas, while 8 pts were metastatic/unresectable. 20 of 31 early stage resected patients
received adjuvant chemotherapy, mainly fluoropirimidine based (17;85%). 13 of them
showed relapse of the disease. Overall, in the cohort of the resected patients we observed
amedian DFS of 14m and amedian OS of 33m. 7 of the 8 unresectable/metastatic pts
received a 5FU and oxaliplatin based first line chemotherapy and 1 of the 8 underwent a
definitive chemoradiation for unresectable primary tumour. The unresectable/meta-
static group showed amedian PFS of 9 m and amedian OS of 26m. In the subgroup of
resected ampullary adenocarcinomaOS was longer for intestinal type respect to biliary
type with amedian value of 40 m and 17m respectively.
Conclusions: According to literature data, our analysis confirm the poor prognosis of
SBA at all stages. Ampullary intestinal adenocarcinomamay have a better prognosis
than ampullary biliary type. Fluropyrimidine based chemotherapy could be an option
in the adjuvant setting and its combination with oxaliplatin could be a valid treatment
for unresectable SBA.
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Background: Small bowel adenocarcinoma (SBA) is a rare disease representing about
1-3% of all gastrointestinal malignancies. Risk factors for SBA include inflammatory
bowel disease and hereditary colorectal cancer syndromes. Moreover, SBA is sometimes
associated with colorectal cancer. Because of its rarity, SBA biology and clinical course
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